Review
Version 2
This version is not peer-reviewed
Immunogenicity of Clinically Relevant SARS-CoV-2 Vaccines in Non-human Primates and Humans
Version 1
: Received: 2 September 2020 / Approved: 7 September 2020 / Online: 7 September 2020 (12:29:06 CEST)
Version 2 : Received: 26 October 2020 / Approved: 27 October 2020 / Online: 27 October 2020 (11:25:32 CET)
Version 2 : Received: 26 October 2020 / Approved: 27 October 2020 / Online: 27 October 2020 (11:25:32 CET)
How to cite: Klasse, P.; Nixon, D.F.; Moore, J.P. Immunogenicity of Clinically Relevant SARS-CoV-2 Vaccines in Non-human Primates and Humans. Preprints 2020, 2020090166 Klasse, P.; Nixon, D.F.; Moore, J.P. Immunogenicity of Clinically Relevant SARS-CoV-2 Vaccines in Non-human Primates and Humans. Preprints 2020, 2020090166
Abstract
Multiple preventive vaccines are being developed to counter the COVID-19 pandemic. The leading candidates have now been evaluated in non-human primates (NHPs) and human Phase 1 and/or Phase 2 clinical trials. Several vaccines have already advanced into Phase 3 efficacy trials, while others will do so before the end of 2020. Here, we summarize what is known of the antibody and T-cell immunogenicity of these vaccines in NHPs and humans. To the extent possible, we compare how the vaccines have performed, taking into account the use of different assays to assess immunogenicity and inconsistencies in how the resulting data are presented. We also summarize the outcome of SARS-CoV-2 challenge experiments in immunized macaques, while noting variations in the protocols used, including but not limited to the virus challenge doses.
Keywords
SARS-CoV-2; S-protein; RBD; COVID-19; neutralizing antibodies; serology; T-cells; vaccines; animal models; Operation Warp Speed
Subject
Medicine and Pharmacology, Immunology and Allergy
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (1)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
Commenter: John Moore
Commenter's Conflict of Interests: Author